Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 26, 2012. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 300,000 Ordinary shares of 25 pence each.
- Purchase Date: April 26, 2012.
- Price Range: Highest price paid was 1,425 pence per share; lowest price paid was 1,415 pence per share.
- Treasury Holdings (Settled): 517,042,927 shares (9.29% of total issued share capital).
- Treasury Holdings (Including Unsettled): 517,342,927 shares (10.25% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,046,490,381 shares.
Material Changes
The filing reports a reduction in the number of shares in issue due to the purchase of 300,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.25% when including unsettled purchases. No other material changes to operations or financial position are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,046,490,381) for calculating disclosure thresholds under FSA rules.
- Confirm the current percentage of voting rights held in Treasury (10.25% including unsettled shares).
- Review the price paid per share (1,415 to 1,425 pence) against market prices on April 26, 2012.
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial results.